Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

By G. Klement, S. Baruchel, J. Rak, S. Man, Katherine A. Clark, D. Hicklin, P. Bőhlen, R. Kerbel. 2000

610 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

VEGF in Signaling and Disease: Beyond Discovery and Development (2019, background): “Several studies have shown that it stems, at least in part, from direct anti-vascular effects of the cytotoxic agents that amplify the pro-apoptotic effects of anti-VEGF agents on the vascular endothelium (Gerber and Ferrara, 2005; Klement et al., 2000; Sweeney et al., 2001).”
Clinical translation of angiogenesis inhibitors (2002, background): “Drug combination-therapy regimens in mice have resulted in prolonged antitumour responses, while avoiding or delaying resistanc”
VEGF-targeted therapy: mechanisms of anti-tumour activity (2008, background): “The principle behind this approach is that the chemotherapy attacks the proliferating endothelial cells while VEGF-targeted therapy diminishes survival signalling in endothelial cells, making them more susceptible to chemotherapy-induced apoptosi”
Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy (2001, background): “Second, acquired drug resistance resulting from genetic and epigenetic mechanisms reduces the effectiveness of available drug”